IUScholarWorks at Indiana University South Bend Engineering Synthetic Antibody Binders for Allosteric Inhibition of Prolactin Receptor Signaling

Background: Many receptors function by binding to multiple ligands, each eliciting a distinct biological output. The extracellular domain of the human prolactin receptor (hPRL-R) uses an identical epitope to bind to both prolactin (hPRL) and growth hormone (hGH), yet little is known about how each hormone binding event triggers the appropriate response. Findings: Here, we utilized a phage display library to generate synthetic antibodies (sABs) that preferentially modulate hPRL-R function in a hormone-dependent fashion. We determined the crystal structure of a sAB-hPRL-R complex, which revealed a novel allosteric mechanism of antagonism, whereby the sAB traps the receptor in a conformation more suitable for hGH binding than hPRL. This was validated by examining the effect of the sABs on hormone internalization via the hPRL-R and its downstream signaling pathway. Conclusions: The findings suggest that subtle structural changes in the extracellular domain of hPRL-R induced by each hormone determine the biological output triggered by hormone binding. We conclude that sABs generated by phage display selection can detect these subtle structural differences, and therefore can be used to dissect the structural basis of receptor-ligand specificity.

[1]  A. Kossiakoff,et al.  Allosteric Control of Ligand Binding Affinity Using Engineered Conformation-Specific Effector Proteins , 2010, Nature Structural &Molecular Biology.

[2]  Patrick England,et al.  Structural characterization of the stem-stem dimerization interface between prolactin receptor chains complexed with the natural hormone. , 2010, Journal of molecular biology.

[3]  Patrick England,et al.  Crystal Structure of an Affinity-matured Prolactin Complexed to Its Dimerized Receptor Reveals the Topology of Hormone Binding Site 2* , 2010, The Journal of Biological Chemistry.

[4]  S. Gadd,et al.  New mechanisms for PRLr action in breast cancer , 2009, Trends in Endocrinology & Metabolism.

[5]  C. Clevenger,et al.  Quantification of PRL/Stat5 signaling with a novel pGL4-CISH reporter , 2008, BMC biotechnology.

[6]  Frederic A. Fellouse,et al.  High-throughput generation of synthetic antibodies from highly functional minimalist phage-displayed libraries. , 2007, Journal of molecular biology.

[7]  Anthony A Kossiakoff,et al.  Crystal structure and site 1 binding energetics of human placental lactogen. , 2006, Journal of molecular biology.

[8]  S. Hankinson,et al.  The role of prolactin in mammary carcinoma. , 2003, Endocrine reviews.

[9]  M. Krieger,et al.  Series introduction: multiligand receptors and human disease. , 2001, The Journal of clinical investigation.

[10]  M. Ultsch,et al.  The X-ray structure of a growth hormone–prolactin receptor complex , 1994, Nature.

[11]  S. Bass,et al.  Zinc mediation of the binding of human growth hormone to the human prolactin receptor. , 1990, Science.

[12]  F. Schmitz,et al.  Expression of functional prolactin and its receptor in human colorectal cancer , 2002, International Journal of Colorectal Disease.